Mallinckrodt plc, together with its subsidiaries, develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands, and Specialty Generics and Amitiza. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone44-0-17-8463-6700
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.22 billion
Profitability
Miscellaneous
Employees3,700
Next Earnings Date2/25/2020 (Estimated)
OptionableOptionable
Mallinckrodt (NYSE:MNK) Frequently Asked Questions
What is Mallinckrodt's stock symbol?
Mallinckrodt trades on the New York Stock Exchange (NYSE) under the ticker symbol "MNK."
How were Mallinckrodt's earnings last quarter?
Mallinckrodt PLC (NYSE:MNK) issued its quarterly earnings data on Tuesday, November, 5th. The company reported $2.07 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.98 by $0.09. The firm had revenue of $743.70 million for the quarter, compared to the consensus estimate of $770.56 million. Mallinckrodt had a negative net margin of 111.44% and a positive return on equity of 24.36%. The company's quarterly revenue was down 7.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.10 EPS. View Mallinckrodt's Earnings History.
When is Mallinckrodt's next earnings date?
What price target have analysts set for MNK?
14 analysts have issued twelve-month target prices for Mallinckrodt's stock. Their forecasts range from $2.00 to $22.00. On average, they anticipate Mallinckrodt's stock price to reach $8.64 in the next year. This suggests a possible upside of 79.5% from the stock's current price. View Analyst Price Targets for Mallinckrodt.
What is the consensus analysts' recommendation for Mallinckrodt?
14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mallinckrodt in the last year. There are currently 1 sell rating, 10 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Mallinckrodt.
Has Mallinckrodt been receiving favorable news coverage?
Press coverage about MNK stock has trended somewhat positive this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Mallinckrodt earned a coverage optimism score of 0.8 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an impact on the company's share price in the near future. View News Stories for Mallinckrodt.
Who are some of Mallinckrodt's key competitors?
Some companies that are related to Mallinckrodt include Alder Biopharmaceuticals (ALDR), Ligand Pharmaceuticals (LGND), Constellation Pharmaceuticals (CNST), Corcept Therapeutics (CORT), Theravance Biopharma (TBPH), Innoviva (INVA), Amneal Pharmaceuticals (AMRX), Esperion Therapeutics (ESPR), BELLUS Health (BLUSF), Y-mAbs Therapeutics (YMAB), TG Therapeutics (TGTX), Endo International (ENDP), Dicerna Pharmaceuticals (DRNA), Intra-Cellular Therapies (ITCI) and Nabriva Therapeutics (NBRV).
What other stocks do shareholders of Mallinckrodt own?
Who are Mallinckrodt's key executives?
Mallinckrodt's management team includes the folowing people:
- Mr. Mark Christopher Trudeau, Pres, CEO & Director (Age 58)
- Dr. Frank Scholz, Exec. VP and Chief Operations & Digital Innovation Officer (Age 50)
- Mr. Matthew K. Harbaugh, Exec. VP & Pres of Specialty Generics (Age 49)
- Mr. Hugh M. O'Neill, Exec. VP & Chief Commercial Officer (Age 56)
- Mr. Bryan M. Reasons, Chief Financial Officer (Age 52)
Who are Mallinckrodt's major shareholders?
Mallinckrodt's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include California Public Employees Retirement System (0.22%), Strs Ohio (0.20%), Eqis Capital Management Inc. (0.15%), Clear Creek Financial Management LLC (0.03%), Beirne Wealth Consulting Services LLC (0.03%) and World Asset Management Inc (0.03%). Company insiders that own Mallinckrodt stock include Bryan M Reasons, James E Flynn and Mark Trudeau. View Institutional Ownership Trends for Mallinckrodt.
Which major investors are selling Mallinckrodt stock?
MNK stock was sold by a variety of institutional investors in the last quarter, including Commerzbank Aktiengesellschaft FI, Strs Ohio, Eqis Capital Management Inc. and Clear Creek Financial Management LLC. View Insider Buying and Selling for Mallinckrodt.
Which major investors are buying Mallinckrodt stock?
MNK stock was acquired by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, Beirne Wealth Consulting Services LLC and World Asset Management Inc. Company insiders that have bought Mallinckrodt stock in the last two years include Bryan M Reasons and Mark Trudeau. View Insider Buying and Selling for Mallinckrodt.
How do I buy shares of Mallinckrodt?
Shares of MNK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Mallinckrodt's stock price today?
One share of MNK stock can currently be purchased for approximately $4.82.
How big of a company is Mallinckrodt?
Mallinckrodt has a market capitalization of $404.89 million and generates $3.22 billion in revenue each year. The company earns $-3,607,000,000.00 in net income (profit) each year or $8.01 on an earnings per share basis. Mallinckrodt employs 3,700 workers across the globe.View Additional Information About Mallinckrodt.
What is Mallinckrodt's official website?
How can I contact Mallinckrodt?
Mallinckrodt's mailing address is 3 LOTUS PARK THE CAUSEWAY STAINES-UPON-THAMES, SURREY X0, TW18 3AG. The company can be reached via phone at 44-0-17-8463-6700 or via email at [email protected]
MarketBeat Community Rating for Mallinckrodt (NYSE MNK)
MarketBeat's community ratings are surveys of what our community members think about Mallinckrodt and other stocks. Vote "Outperform" if you believe MNK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNK will underperform the S&P 500 over the long term. You may vote once every thirty days.
